Instrument Inactif

Communiqués Depomed Inc Nasdaq

Actions

US2499081048

Produits pharmaceutiques

Communiqués

16/06	Assertio Announces Completion of Merger with Zydus Lifesciences and Fundamental Change and Make-Whole Fundamental Change Relating to its Outstanding 6.50% Convertible Senior Notes due 2027	BU
19/05	Assertio Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Assertio Holdings, Inc. - ASRT	BU
13/05	Assertio to Be Acquired by Zydus Worldwide DMCC for $23.50 Per Share in Cash	BU
08/05	Assertio and Garda Mutually Agree to Delay Launch of Tender Offer	BU
05/05	Assertio and Garda Mutually Agree to Postpone Commencement of Tender Offer	BU
04/05	Assertio Announces Amended and Restated Merger Agreement with Garda Therapeutics	BU
29/04	Assertio and Garda Mutually Agree to Extend Tender Offer Deadline	BU
21/04	Assertio Provides Update on Garda Therapeutics Tender Process	BU
14/04	Assertio Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Assertio Holdings, Inc. - ASRT	BU
13/04	ASRT Stock Alert: Halper Sadeh LLC is Investigating Whether Assertio Holdings, Inc. is Obtaining a Fair Price for its Shareholders	BU
08/04	Assertio Announces Agreement to be Acquired by Garda Therapeutics	BU
16/03	Assertio: Q4 Earnings Snapshot	AQ
16/03	Assertio Reports Fourth Quarter and Full Year 2025 Financial Results	BU
03/03	Assertio Holdings, Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on March 16, 2026	BU
12/01	Assertio Holdings, Inc. Regains Compliance With Nasdaq Listing Requirements	BU
09/01	Assertio Announces Publication of Rolvedon® Same-Day Dosing Clinical Trial	BU
22/12	Assertio Holdings, Inc. Announces 1-for-15 Reverse Stock Split	BU
10/11	Assertio: Q3 Earnings Snapshot	AQ
10/11	Assertio Reports Third Quarter 2025 Financial Results	BU
28/10/25	Assertio Announces Leadership Transition	AQ
23/09/25	CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Spectrum Pharmaceuticals (NASDAQ: SPPI) Investors to Inquire About a Securities Fraud Class Action by September 24, 2025	PR
15/09/25	Assertio Presents First-Ever Real-World Study Showing Patient Experience with SYMPAZAN® (clobazam) Oral Film, CIV	AQ
12/09/25	DEADLINE APPROACHING: Berger Montague Advises Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) Investors to Inquire About a Securities Fraud Class Action by September 24, 2025	PR
10/09/25	Assertio to Present New Data from Real-World Evidence Study of SYMPAZAN® at upcoming 150th Annual Meeting of the American Neurological Association	AQ
08/09/25	SPECTRUM PHARMACEUTICALS (NASDAQ: SPPI) CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Investors to Inquire About a Securities Class Action by September 24, 2025	PR